Murao S, Gemmell M A, Callaham M F, Anderson N L, Huberman E
Cancer Res. 1983 Oct;43(10):4989-96.
Human promyelocytic leukemia cells (HL-60) were induced to differentiate into macrophage-like cells in a dose (3 X 10(-10) to 10(-7) M) and time (1 to 6 days)-dependent manner by 1,25-dihydroxyvitamin D3 and the tumor promoter, phorbol-12-myristate-13-acetate. Differentiation was determined by an increase in the percentage of morphologically mature cells, in lysozyme and nonspecific esterase activities, and in reactivity with the murine OKM1 monoclonal antibody. Two HL-60 cell variants, designated as R-80 and B-II, were also examined. R-80 cells, which are resistant to induction of cell differentiation by phorbol-12-myristate-13-acetate, also exhibited resistance, although to a lesser degree, to induction of cell differentiation by 1,25-dihydroxyvitamin D3. The resistance to the action of the two compounds is presumably not due to similar binding sites for the two inducers, since 1,25-dihydroxyvitamin D3 was unable to compete for the phorbol diester binding sites as measured by [3H]phorbol-12,13-dibutyrate binding. B-II cells were resistant to induction of cell differentiation by 1,25-dihydroxyvitamin D3, phorbol-12-myristate-13-acetate, retinoic acid, and dimethyl sulfoxide. Two-dimensional electrophoretic analysis of HL-60 cell protein patterns indicated that treatment of the HL-60 cells with 1,25-dihydroxyvitamin D3, phorbol-12-myristate-13-acetate, retinoic acid, and dimethyl sulfoxide caused the cells to express various monocyte-macrophage and granulocyte marker proteins. None of the inducers caused a protein pattern identical to that of peripheral monocytes or granulocytes in the HL-60 cells, but the protein pattern of the HL-60 cells treated with 1,25-dihydroxyvitamin D3 was the closest to that of peripheral blood monocytes. These results indicate that 1,25-dihydroxyvitamin D3 induces in the HL-60 cells a phenotype that resembles, but is not identical to, that of peripheral monocytes-macrophages.
人早幼粒细胞白血病细胞(HL-60)在1,25-二羟基维生素D3和肿瘤促进剂佛波醇-12-肉豆蔻酸酯-13-乙酸酯作用下,以剂量(3×10⁻¹⁰至10⁻⁷M)和时间(1至6天)依赖的方式诱导分化为巨噬细胞样细胞。通过形态学成熟细胞百分比、溶菌酶和非特异性酯酶活性以及与鼠OKM1单克隆抗体的反应性增加来确定分化。还检测了两个HL-60细胞变体,命名为R-80和B-II。R-80细胞对佛波醇-12-肉豆蔻酸酯-13-乙酸酯诱导的细胞分化具有抗性,对1,25-二羟基维生素D3诱导的细胞分化也表现出抗性,尽管程度较轻。对这两种化合物作用的抗性可能不是由于两种诱导剂具有相似的结合位点,因为通过[³H]佛波醇-12,13-二丁酸酯结合测定,1,25-二羟基维生素D3无法竞争佛波醇二酯结合位点。B-II细胞对1,25-二羟基维生素D3、佛波醇-12-肉豆蔻酸酯-13-乙酸酯、视黄酸和二甲亚砜诱导的细胞分化具有抗性。HL-60细胞蛋白质图谱的二维电泳分析表明,用1,25-二羟基维生素D3、佛波醇-12-肉豆蔻酸酯-13-乙酸酯、视黄酸和二甲亚砜处理HL-60细胞会使细胞表达各种单核细胞-巨噬细胞和粒细胞标记蛋白。在HL-60细胞中,没有一种诱导剂能使蛋白质图谱与外周血单核细胞或粒细胞的图谱相同,但用1,25-二羟基维生素D3处理的HL-60细胞的蛋白质图谱最接近外周血单核细胞的图谱。这些结果表明,1,25-二羟基维生素D3在HL-60细胞中诱导出一种类似于但不同于外周血单核细胞-巨噬细胞的表型。